Abstracts tagged "interstitial lung disease"

Abstract Number: 0290 • ACR Convergence 2021
Prevalence and Predictors of Mortality in Rheumatoid Arthritis-Related Lung Disease: Results from a Single Center Study
Didem Sahin Eroglu¹, Anil Colaklar², Serdar Baysal³, Murat Torgutalp¹, Asaf Baygul⁴, Serdar Sezer¹, Emine Aydemir Guloksuz¹, Mehmet Yuksel¹, Mucteba Yayla¹, Emine Uslu yurteri⁵, Caglar Uzun², Ozlem Ozdemir kumbasar⁴, Murat Turgay¹, Kinikli Gulay¹ and Askin Ates¹, ¹Ankara University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ²Ankara University Faculty of Medicine, Department of Radiology, Ankara, Turkey, ³Ankara University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, ⁴Ankara University Faculty of Medicine, Department of Pulmonology, Ankara, Turkey, ⁵Hatay Training and Research Hospital, Hatay, Turkey
Background/Purpose: Rheumatoid arthritis-related lung disease (RA-LD) is a common manifestation of rheumatoid arthritis (RA) and associated with excess mortality. Many studies to date were focused…
Abstract Number: 0561 • ACR Convergence 2021
Enhancing the Identification of Rheumatoid Arthritis-Associated Interstitial Lung Disease in Electronic Health Records Through Text Mining of Computerized Tomography Reports
Brent Luedders¹, Brendan Cope², Matt Devries², W. Scott Campbell², James Campbell², Ted Mikuls³, Jeffrey Curtis⁴, Daniel Hershberger³ and Bryant England³, ¹University of Nebraska Medical Center, Omaha, NE, United Kingdom, ²University of Nebraska Medical Center, Omaha, ³University of Nebraska Medical Center, Omaha, NE, ⁴Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Interstitial lung disease (ILD) is an extraarticular manifestation of RA that leads to increased morbidity and mortality. Algorithms incorporating multiple diagnostic and procedure codes…
Abstract Number: 1372 • ACR Convergence 2021
Outcomes and Risk Factors for Respiratory Failure in Patients with Scleroderma Associated with ILD
Soumyasri Kambhatla¹, Augustine Manadan² and Amy Trang², ¹Rush University, Chicago, IL, ²Rush University Medical Center, Chicago, IL
Background/Purpose: Scleroderma is associated with underlying ILD. About 48% those with diffuse cutaneous SSc and 26% of those with limited cutaneous SSc were found to…
Abstract Number: 1846 • ACR Convergence 2021
Effect of Nintedanib in Patients with Systemic Sclerosis-associated Interstitial Lung Disease and Risk Factors for Rapid Decline in Forced Vital Capacity: Further Analyses of the SENSCIS Trial
Dinesh Khanna¹, Toby M Maher², Elizabeth Volkmann³, Yannick Allanore⁴, Vanessa Smith⁵, Shervin Assassi⁶, Michael Kreuter⁷, Anna-Maria Hoffmann-Vold⁸, Masataka Kuwana⁹, Christian Stock¹⁰, Margarida Alves¹¹, Steven Sambevski¹¹ and Christopher Denton¹², ¹University of Michigan, Ann Arbor, MI, ²National Heart and Lung Institute, Imperial College London, UK, National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, and Keck School of Medicine, University of Southern California, Los Angeles, CA, ³Department of Medicine, Division of Rheumatology, University of California, David Geffen School of Medicine, Los Angeles, CA, ⁴Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, ⁵Department of Rheumatology and Internal Medicine, Ghent University Hospital, Ghent, Belgium, ⁶University of Texas McGovern Medical School at Houston, Houston, TX, ⁷Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Care Medicine, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany, ⁸Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ⁹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ¹⁰Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, ¹¹Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ¹²University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom
Background/Purpose: In the SENSCIS trial conducted in a population of subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD), with a mean time since onset of…
Abstract Number: 0291 • ACR Convergence 2021
IgA Anti-Cyclic Citrullinated Peptide Antibodies in Bronchoalveolar Lavage Fluid from Patients with Idiopathic Pulmonary Fibrosis Are Associated with Reduced Mortality
Scott Matson¹, Candace Cephers², Timothy Wilson³, Valerie Minarchick³, Kevin Brown⁴, Joshua Solomon⁴ and Kristen Demoruelle⁵, ¹University of Kansas, Kansas City, MO, ²St Joseph Hospital, Internal Medicine, Denver, CO, ³University of Colorado, Denver, CO, ⁴National Jewish Health, Denver, CO, ⁵University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Idiopathic pulmonary fibrosis (IPF) is a form of interstitial lung disease (ILD) that shares many clinical features with rheumatoid arthritis (RA) associated ILD. Our…
Abstract Number: 0566 • ACR Convergence 2021
Natural Language Processing of Electronic Health Record Notes Captures Forced Vital Capacity in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Punyasha Roul¹, Yangyuna Yang¹, Daniel Hershberger¹, Ted Mikuls¹, Jorge Rojas², Jeffrey Curtis³, Joshua Baker⁴, Brian Sauer⁵ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²VA Puget Sound, Seattle, WA, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵University of Utah, Salt Lake City, UT
Background/Purpose: Rheumatoid arthritis-interstitial lung disease (RA-ILD) has a poor long-term prognosis, including premature mortality. Longitudinal monitoring of patients in clinical and clinical trial settings includes…
Abstract Number: 1379 • ACR Convergence 2021
Serum Levels of the Soluble Receptor for Advanced Glycation Endproducts Are Prospectively Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis
Isabella Atzeni¹, Yehya Al-Adwi², Berber Doornbos-van der Meer², Anniek Van Roon², Caroline Roozendaal¹, Andries Smit², Alja J. Stel², Harry Van Goor², Tji-Joong Gan¹, Johanna Westra² and Douwe J Mulder², ¹University of Groningen, University Medical Centre Groningen, Groningen, Groningen, Netherlands, ²University of Groningen, University Medical Centre Groningen, Groningen, Netherlands
Background/Purpose: Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are the leading causes of death in Systemic Sclerosis (SSc). Markers for early detection of…
Abstract Number: 1847 • ACR Convergence 2021
Severity of Gastroesophageal Reflux, but Not the Use of Proton Pump Inhibitors, Is Associated with Radiographic Progression of Interstitial Lung Disease in Systemic Sclerosis
Elizabeth Volkmann¹, Donald Tashkin², Mei Leng², Grace Kim², Jonathan Goldin² and Michael Roth², ¹Department of Medicine, Division of Rheumatology, University of California, David Geffen School of Medicine, Los Angeles, CA, ²University of California Los Angeles, Los Angeles, CA
Background/Purpose: Esophageal dysmotility is a common feature of systemic sclerosis (SSc) and aspiration of gastric contents may serve as an inciting and/or exacerbating factor in…
Abstract Number: 0294 • ACR Convergence 2021
Comparison of Factors Associated with CT-Scan Progression of Interstitial Lung Disease in Rheumatoid Arthritis and Idiopathic Pulmonary Fibrosis. Retrospective Multicenter Study of 144 Patients
Charlotte Lucas¹, Aurore Tremblay¹, Thibaut Lapotre², Stéphane Jouneau³, Mathieu Lederlin² and Aleth Perdriger¹, ¹Rheumatology department, University Hospital, Rennes, France, ²Radiology Department, University Hospital, Rennes, France, ³Department of Respiratory Medicine, Competences Centre for Rare Pulmonary Diseases, Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France, Rennes, France
Background/Purpose: Compare factors associated with interstitial lung disease (ILD) progression determined on CT-scan analysis and survival in two distinct populations, patients with rheumatoid arthritis associated…
Abstract Number: 0574 • ACR Convergence 2021
Prevalence and Early Progression of Lung Diseases in Patients with Recently-Diagnosed Rheumatoid Arthritis: A Prospective Cohort Study
Tina Mahajan¹, Daniel Hershberger¹, Matt Devries², Punyasha Roul¹, Yangyuna Yang¹, Sherrie Edwards¹, Geoffrey Thiele¹, Ted Mikuls¹, James O'Dell¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha
Background/Purpose: Several types of lung diseases complicate the rheumatoid arthritis (RA) disease course such as interstitial lung disease (ILD) and obstructive lung diseases. The prevalence…
Abstract Number: 1381 • ACR Convergence 2021
Chemokines CCL2 and CCL17 as Potential Serum Biomarkers for Interstitial Lung Disease in Systemic Sclerosis
Imon Barua¹, Håvard Fretheim², Hilde Jenssen Bjørkekjær³, Henriette Didriksen⁴, Oyvind Midtvedt², Trond Mogens AAløkken², Torhild Garen⁵, Oyvind Molberg⁶, John Belperio⁷ and Anna-Maria Hoffmann-Vold¹, ¹Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway, ³Department of Rheumatology, Sørlandet sykehus HF, Kristiansand, Norway, ⁴Oslo University Hospital, Moss, Norway, ⁵Department of Rheumatology, Oslo University Hospital, Oslo, Nepal, ⁶Oslo University Hospital, Oslo, Nepal, ⁷University of California Los Angeles Interstitial Lung Disease Center, Los Angeles, CA
Background/Purpose: Systemic sclerosis (SSc) carries high risk for progressive interstitial lung disease (ILD). Several anti-inflammatory therapies have been used to treat SSc-ILD and recently the…
Abstract Number: 1850 • ACR Convergence 2021
Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Two-Year Data from SENSCIS-ON
Yannick Allanore¹, Madelon C Vonk², Oliver Distler³, Arata Azuma⁴, Maureen Mayes⁵, Martina Gahlemann⁶, Alexandra James⁷, Veronika Kohlbrenner⁸, Margarida Alves⁹, Dinesh Khanna¹⁰ and Kristin B Highland¹¹, ¹Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, ²Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland, ⁴Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, ⁵Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ⁶Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ⁷Elderbrook solutions GmbH, Bietigheim-Bissingen, Germany, Bietigheim-Bissingen, Germany, ⁸Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, ⁹Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Cleveland Clinic, Cleveland, OH
Background/Purpose: In the SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) (mL/year) over 52 weeks by…
Abstract Number: 0279 • ACR Convergence 2020
Pulmonary Involvement in a Single Center Cohort of Patients with Systemic Lupus Erythematosus
Naci Senkal¹, Esen Kiyan², Elif Kocasoy-Orhan³, Ali Demir⁴, Mehmet Aydogan⁵, Yasemin Yalcinkaya⁶, Ahmet Gul⁶, Murat Inanc⁷, Mahdume Lale Öcal⁶ and Bahar Artım-Esen⁶, ¹Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, ²Department of Chest Disease, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, ³Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, ⁴Fulya Radiologic Imaging Center, İstanbul, Turkey, ⁵Department of Cardiology, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, ⁶Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, İstanbul, Turkey, ⁷Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
Background/Purpose: The prevalence of SLE pulmonary involvement varies depending on several factors, including diagnostic methods. In this study, we sought to determine the frequency of…
Abstract Number: 1049 • ACR Convergence 2020
Effects of Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-related Interstitial Lung Diseases (ILDs) in the INBUILD Trial: Subgroups by HRCT Pattern
Paul Dellaripa¹, Martin Aringer², Anna Maria Hoffmann-Vold³, Clive Kelly⁴, Shikha Mittoo⁵, Alexandra James⁶, Klaus Rohr⁶, Susanne Stowasser⁶ and Yoshikazu Inoue⁷, ¹Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA, Boston, MA, ²Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, Dresden, Germany, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁴Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, Newcastle upon Tyne, United Kingdom, ⁵University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁷Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai City, Osaka, Japan, Sakai City, Osaka, Japan
Background/Purpose: In the INBUILD trial, nintedanib reduced the rate of decline in forced vital capacity (FVC) over 52 weeks compared with placebo in patients with…
Abstract Number: 1194 • ACR Convergence 2020
MUC5B Promoter Variant rs35705950 and Risk Stratification for Rheumatoid Arthritis – Interstitial Lung Disease
Pierre-Antoine Juge¹, Fabienne Louis-Sidney², Benjamin Granger³, Joanna Kedra⁴, Marie-Pierre Debray⁵, Esther Ebstein¹, Raphaël Borie⁶, Arnaud Constantin⁷, Bernard Combe⁸, Rene-Marc Flipo⁹, Xavier Mariette¹⁰, Olivier Vittecoq¹¹, Alain Saraux¹², Guillermo Carvajal Alegria¹³, Jean Sibilia¹⁴, Francis Berenbaum¹⁵, Caroline Kannengiesser¹⁶, Bruno Crestani⁶, Catherine Boileau¹⁶, Bruno Fautrel¹⁷ and Philippe Dieude¹⁸, ¹Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ²Service de Rhumatologie, CHU de Fort de France, Martinique, France, Fort de France, France, ³Département de Biostatistiques, Santé Publique et Information Médicale, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Paris, France., Paris, France, ⁴Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, UMR S1136, Paris, France, Paris, France, ⁵Université de Paris, Service de Radiologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ⁶Université de Paris, Service de Pneumologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ⁷Hospital Pierre Paul Riquet, Toulouse, France, ⁸University of Montpellier, Montpellier, France, ⁹Lille University Hospital, Lille, France, ¹⁰Paris-Sud University, Rueil-Malmaison, France, ¹¹University Hospital of Rouen, Rouen, France, ¹²Department of Rheumatology, UBO, CHU, INSERM 1227 (LBAI), Brest, France, ¹³CHU de Brest, Service de Rhumatologie, Brest, France, ¹⁴CHU Strasbourg, Service de Rhumatologie, Strasbourg, France, ¹⁵AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, ¹⁶Université de Paris, Hôpital Bichat, Service de Génétique, AP-HP, Paris, Paris, France, ¹⁷Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ¹⁸Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Interstitial lung disease (ILD) is an extra-articular manifestation of rheumatoid arthritis (RA) detected in 20 to 60% of patients with RA on high-resolution computed-tomography…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].